Fundamentals

Symbion Health's business divisions

Symbion Health Limited is a leading Australian health, diagnostic and wellness company.   It provides diagnostic and wellness services through its pathology, diagnostic imaging, medical centres and pharmacy services divisions as well as health-related products through its consumer division.

Symbion Pathology: is one of Australia's leading private pathology groups with more than 150 pathologists and 6000 scientists, collection and support staff.  More than 10 million patient espisodes are performed annually in approixmately 80 laboratories and 660 collection centres.

Symbion Medical Centres: works with General Practitioners to provide primary healthcare and family medicine to local communities around Australia.  Approximately 450 General Practitioners operate their practices in more than 50 Symbion Medical Centres.

Symbion Imaging: is one of Australia's largest diagnostic imaging groups operating in over 120 community and hospital based centres in New South Wales, Queensland and Victoria.  Approximately 180 imaging specialists perform more than 2.2 million examinations annually.

Symbion Pharmacy Services: provides wholesale distribution of pharmaceutical and healthcare product lines to around 3000 retail pharmacies, as well as public and private hospitals.  Its trusted and recognised pharmacy retail brands include Terry White Chemists® and Chemmart®.  Symbion Pharmacy Services also supports independent retail pharmacies with its Pharmacy Choice® program and provides market-leading pharmacy software solutions, MINFOS® and MINFOS® multistore.

Symbion Consumer: is a leading provider of nutaceuticals (vitamin and mineral supplements) with over 1.3 billion tablets and capsules produced annually.  Symbion Consumer manufactures more than 75% of its nutraceutical products and its well known brands include Nature's Own®, Bio-Organics®, Cenovis® and Betadine®.

Pro-forma* financial highlights

 Year ending 30 June  2005  Annual growth
 Revenue $3.2 billion  5.2% 
 EBITA $153.4 million 10.1% 
 EBIT $112.6 million 10.8%
 Net operating cash flows  $184.3 million** 28.1%

* The pro-forma financial information is prepared under Australian GAAP by combining the historical financial information of Symbion Pathology, Symbion Imaging, Symbion Pharmacy Services and Symbion Consumer. Pro-forma adjustments are made to the historical financial information to adjust for material discontinued activities, to exclude the impact of certain non-recurring items and to reflect the costs of operating as an independent company.

** Excludes proceeds from Pharmacy debtors' securitisation of $184 million. 

Key Management

Robert Cooke, CEO and Managing Director

Mark Hooper, Chief Financial Officer